Pulmonary Hypertension News Forums › Forums › Research and Development › Phase 2 Trial of Potential Therapy for PH Related to Left Heart Disease Soon to Begin Enrolling Patients

  • Research & Development

    Phase 2 Trial of Potential Therapy for PH Related to Left Heart Disease Soon to Begin Enrolling Patients

    Posted by Pulmonary Hypertension News Moderator on June 11, 2018 at 5:23 pm

    A new Phase 2 study evaluating Tenax Therapeutic’s investigational levosimendan as a therapy for pulmonary hypertension (PH) associated with heart failure and preserved left ventricular ejection fraction (PH-HFpEF) — a type of PH related to left heart disease – will soon begin recruiting participants, the company announced. The trial, due to open in August, will enroll 36 people with PH-HFpEF to test whether levosimendan can improve hemodynamic measures (related to blood flow) as seen in exercise capacity and functional abilities.

    Read more about this upcoming trial here: Phase 2 Trial of Potential Therapy for PH Related to Left Heart Disease Soon to Begin Enrolling Patients

    Are you familiar with the drug levosimendan? What are your thoughts on this trial?

    replied 5 years, 11 months ago 1 Member · 0 Replies
  • 0 Replies

Sorry, there were no replies found.

Log in to reply.

Start of Discussion
0 of 0 replies June 2018
Now

Report

Harassment or bullying behavior
Contains mature or sensitive content
Contains misleading or false information
Contains abusive or derogatory content
Contains spam, fake content or potential malware

Block Member?

Please confirm you want to block this member.

You will no longer be able to:

  • See blocked member's posts
  • Mention this member in posts
  • Invite this member to groups
  • Message this member
  • Add this member as a connection

Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.

Report

You have already reported this .